论文部分内容阅读
目的:研究头孢三嗪、头孢噻肟和头孢呋辛治疗下呼吸道感染的成本及影响因素。方法:采用前瞻性随机临床试验和成本测算的方法,计算下呼吸道感染患者的成本,分析影响成本大小的因素。结果:头孢三嗪、头孢噻肟和头孢呋辛治疗下呼吸道感染患者的成本分别为3394.8,3765.9和3736.1元,治疗药物和疾病的严重程度是影响成本的因素。结论:与头孢噻肟和头孢呋辛相比,头孢三嗪治疗下呼吸道感染的成本最小,在评价一个药物的治疗成本时必须考虑疾病严重程度对其的影响。
Objective: To study the cost and influencing factors of ceftriaxone, cefotaxime and cefuroxime in the treatment of lower respiratory tract infection. Methods: The prospective randomized clinical trial and cost estimation method were used to calculate the cost of patients with lower respiratory tract infection, and to analyze the factors influencing cost size. Results: The costs of ceftriaxone, cefotaxime and cefuroxime in the treatment of patients with lower respiratory tract infection were 3394.8, 3765.9 and 3736.1 yuan, respectively. The cost of the treatment drugs and the severity of the disease were the factors affecting the cost. CONCLUSIONS: Ceftriaxone has the lowest cost of lower respiratory tract infection compared with cefotaxime and cefuroxime, and its effect on disease severity should be considered when evaluating the cost of treatment of a drug.